Healing in Motion: My Journey With Physical Therapy After Breast Cancer Treatment
A few months after my breast cancer surgery, I underwent radiation therapy. I hadn't yet considered physical therapy, but I remember the exact moment I realized just how necessary it was. I was reaching for something – I don't recall what – but I couldn't lift my arm high enough to grab it. I tried to move slowly, hoping that would help, but no matter what I did, my arm stopped short. I had just turned 33 and thought to myself, 'This can't be my reality going forward.' At my next appointment, I shared my limited range of motion with my oncologist. She recommended physical therapy – and thus, a new challenge began.
I was lucky to find a physical therapist near my home who specialized in oncology. We began with an evaluation and consultation. My second session was tough. So were the many that followed. I remember feeling weak and defeated; the pain brought me to tears. But deep down, I knew the journey would be worth it.
Little by little, I began to see progress – not only in my range of motion but in the way my body felt. The persistent pain and tightness that had restricted me started to melt away. With each session, I gained something invaluable: hope, strength, and a deep appreciation for movement.
My therapy included targeted massages, scar tissue work, and icing after each visit. I truly believe this hands-on care enhanced my recovery. The scar massage, in particular, helped with both healing and the overall appearance and texture of my skin.
One of the things I loved most about my physical therapy plan was its simplicity. Most of the stretches and exercises could be done at home, with little to no equipment. Resistance bands and a foam roller were helpful but not required – unless prescribed by your therapist.
What I learned along the way:
Your body has already endured so much. Be patient. Be kind. Celebrate how far you've come, even on the tough days. Physical therapy taught me not only how to regain strength, but how to honor my healing. It's important to know: It's never too late to start physical therapy. But the sooner you begin, the sooner you'll start feeling better – physically, emotionally, and mentally. You deserve to treat yourself gently and embrace every small victory.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Pregnant Woman, 29, Thought She Had Morning Sickness. Then, She Was Diagnosed with a Fast-Growing Cancer
"I went from looking at prams and cots to looking at wigs," the woman told SWNS NEED TO KNOW A pregnant woman who thought she had morning sickness was eventually diagnosed with a fast-growing cancer Sophia Yasin, 29, of Middlesbrough, England, said she was experiencing intense nausea, night sweats and itchiness before her diagnosis She said people around her assured her that her symptoms were 'normal' and would subside with time A pregnant woman thought her extreme nausea was simply morning sickness — until she received a life-altering cancer diagnosis. Sophia Yasin, 29, of Middlesbrough, England, became pregnant in June 2024. The housing support worker and her husband had just purchased a home, and they were looking forward to the future ahead, per SWNS. It was around that time when Sophia began experiencing a host of unpleasant symptoms. "I was [vomiting] all day, every few hours. I was getting night sweats and itchiness through the night. I was very uncomfortable,' she told the outlet. Sophia said people around her told her not to worry, reassuring her that this was all 'normal.' "Everyone told me it was very normal in the first trimester and should ease up,' she recalled, adding, 'I did have some worry, but I thought it was normal for my first pregnancy.' However, her situation took a sudden turn when she collapsed at work at the beginning of her second trimester. "I remember seeing black, and I blacked out,' she told SWNS. Sophia was rushed to the local hospital, where doctors initially suspected she had pneumonia. However, scans and a biopsy revealed that she had a tumor over her heart. She was diagnosed with pre-mediastinal large B-cell non-Hodgkin's lymphoma — a type of cancer that affects the lymphatic system — in September 2024. Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. "I remember saying, 'What does this mean for the baby?' I remember being numb,' Sophia said. The doctors told Sophia that the tumor over her heart was growing fast, and that she needed to begin chemotherapy immediately if she had any chance of survival. However, treatment could also harm or lead to the death of her unborn child. Sophia and her husband ultimately made the difficult decision to terminate the pregnancy based on the many medical variables at hand. While Sophia was devastated by the loss of her pregnancy, she also acknowledged that it may have saved her life. 'Because I was pregnant, I was prioritized [within the health care system]. In a way, because I was pregnant, they found the cancer in time," she told SWNS. Sophia said she was forced to fight for her next chapter while also grieving the loss of what could have been. "I was grieving a baby but trying to have treatment,' she recalled. She added, 'I lost a lot in a short period of time. I went from looking at prams and cots to looking at wigs. I lost my hair, my baby and my old life." Sophia officially went into remission in January 2025 after six rounds of chemotherapy — but she said she has not forgotten the baby she lost — a daughter whom she and her husband named Kainaat Pearl. She told the outlet that she would like to try for a child again, but that doctors have advised her to wait two years, as there is an increased risk of the cancer returning within that window. Sophia has since established a GoFundMe for a fundraising walk to benefit Lymphoma Action, a U.K. charity dedicated to lymphoma. 'Last summer, my world changed forever,' Sophia wrote on the fundraising page. 'In the midst of what should have been one of the happiest times of my life, I faced the unimaginable: fighting for my life while having to say goodbye to my baby girl, Kainaat Pearl.' 'Every step we take is for Kainaat, for those still fighting and for those we've lost,' she added. The GoFundMe has raised $1,356 toward a goal of $1,490. Read the original article on People
Yahoo
10 hours ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool
Yahoo
11 hours ago
- Yahoo
Trump's Foreign Aid Cuts Are Ruining Ethiopia's Progress on Maternal Mortality
And enabling the country's anti-abortion movement. Since January, Donald Trump has–surprise!–inflicted an innumerable amount of devastation on reproductive rights and maternal health. If you're a regular Jezebel reader, you know this is nothing new. But a new report by the Independent reveals the wickedness isn't just barbaric–it's global. The article focuses on Ethiopia, how it once 'won the battle against its maternal deaths crisis,' and well, how Trump's foreign aid cuts might just ruin the progress. In 2005, the country repealed its draconian abortion ban, which only permitted the procedure to save the mother's life or her health (sound familiar?). In the two decades since, abortion has been legal in cases of rape, incest, fetal abnormalities, among other exceptions. The progress thereafter was significant. A paper published in May 2024 revealed that during the first 20 years of the 21st century, the country had slashed its maternal death rate by 72% and neonatal death rate by 44%—an impressive feat compared to other governments in sub-Saharan Africa. Most Popular George Clooney Sounds Like a Lovely House Husband Ohio Woman Faces 'Abuse of a Corpse' Charge for Miscarriage in Another Post-Roe Nightmare Abortion Access Will, Once Again, Be Decided by the Supreme Court But between canceling 83% of USAID programs in March and slashing away billions of aid through the One Big Beautiful (I-am-so-sick-and-tired-of-this) Bill, legislators have essentially deserted aid organizations around the world and left thousands to cope without life-saving treatments. For Ethiopia, one of the largest beneficiaries of U.S. aid dollars, it has also meant shutting down healthcare providers. Funding cuts have 'significantly affected accessibility of services including family planning, maternal health services, even newborn, child health, adolescent, and youth health services,' Dr. Hailemariam Segni, the president of the Ethiopian Society of Obstetrics and Gynecology, explained to the outlet. Still, he predicts that 'the number of pregnancies will increase'—and with it, so will the complications. The Independent writes: With the dust settling after Trump ordered all foreign aid work to stop in January of this year, Ethiopia has come out as one of the biggest losers in the cuts. By March, the country had seen the second biggest cut by dollar amount, tied with the Democratic Republic of Congo and exceeded only by funding cuts to Ukraine, according to the Center for Global Development. Dr Shibru says 85 per cent of NGOs, crucial in the delivery of many of the country's health services, had stopped work or were shuttered. A quick refresher that foreign aid cuts aren't just sadistic and cruel, they're unnecessary. It's not about 'fiscal conservatism': the federal government spends just a paltry 1% of its budget on foreign aid—a literal drip in the bucket. It's not 'America First': it's a huge erosion of U.S. influence and a huge shake-up to the very institutions it set up in the first place (not that any said institutions are perfect–but that's a fight for another time). And any reproductive health or family planning organization abroad that so much as whispers the word 'abortion' gets its funding slashed by Trump's global gag rule. So much for the party of 'family values. Unfortunately, funding cuts are just the tip of the iceberg. Conceringly, there's a growing 'resurgent anti-rights movement' that wants to roll back the country's 2005 law–and with it, access to safe abortion. Because of this, fewer Ethiopians are accessing abortions through public facilities, according to data collected by the country's Ministry of Health, That's right, anti-abortionists in America are enabling a global ripple effect. And because aid cuts are creating a vacuum, another doctor explains, anti-abortion groups are getting new energy—and the opportunity—to step in. Even if Ethiopia manages to stave off its anti-abortionists, none of the cuts bode well for a country whose maternal mortality rate was steadily decreasing up until now. So well done, America. You've not just managed to up your own maternal death crisis–but you've sabotaged others', too. Yay. Like what you just read? You've got great taste. Subscribe to Jezebel, and for $5 a month or $50 a year, you'll get access to a bunch of subscriber benefits, including getting to read the next article (and all the ones after that) ad-free. Plus, you'll be supporting independent journalism—which, can you even imagine not supporting independent journalism in times like these? Yikes.
